Trial
NCT06108739
ATG Plus Low-dose PT-Cy for GVHD Prevention
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Peking University People's Hospital
Collaborators
—
Condition
Hematologic Malignancy
Intervention
Cyclophosphamid
Why stopped
DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-03